Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/876343/000149315221010348/form8-k.htm
March 2024
March 2024
February 2024
February 2024
November 2023
September 2023
August 2023
June 2023
May 2023
May 2023
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/876343/000149315221010348/form8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Lineage Cell Therapeutics, Inc..
Lineage Cell Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Material Contracts, Statements, Certifications & more
Lineage Cell Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: LCTXEvents:
CIK: 876343
Form Type: 8-K Corporate News
Accession Number: 0001493152-21-010348
Submitted to the SEC: Mon May 03 2021 5:00:18 PM EST
Accepted by the SEC: Mon May 03 2021
Period: Monday, May 3, 2021
Industry: Biological Products No Disgnostic Substances